Remdesivir
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Remdesivir
- Pharmacist Assessment Report
- Remdesivir: From Antiviral Therapy (Original Indication Not Specified) to Multiple Endocrine Neoplasia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Remdesivir: From Antiviral Therapy (Original Indication Not Specified) to Multiple Endocrine Neoplasia
One-Sentence Summary
Remdesivir is a nucleotide analog antiviral, marketed in Canada as VEKLURY. The Health Canada record compiled for this report does not state its approved indication. The TxGNN model’s top-ranked prediction is multiple endocrine neoplasia (score 0.9950), but there are 0 clinical trials and 0 publications supporting it. The prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Health Canada record |
| Predicted New Indication | Multiple endocrine neoplasia |
| TxGNN Prediction Score | 0.9950 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general knowledge, remdesivir is a nucleotide analog prodrug that inhibits viral RNA-dependent RNA polymerase (RdRp). Its established use is in viral disease, with the literature centred on COVID-19.
The predicted indication, multiple endocrine neoplasia, is a hereditary tumor syndrome (for example MEN1 or RET mutations) with no viral cause. No mechanistic link could be identified. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other predictions were also reviewed:
- HIV infectious disease (score 0.9932, L4): This is the most evidence-rich prediction, but the retrieved literature is almost entirely about COVID-19. HIV replicates via reverse transcriptase and integrase, not RdRp, so direct activity is not established.
- Feline AIDS and simian immunodeficiency virus infection: These are animal diseases predicted through HIV similarity, with no evidence for remdesivir.
- Prinzmetal angina, homozygous familial hypercholesterolemia, antithrombin deficiency type 2 and a rare neurodevelopmental disorder: There is no plausible mechanism and no evidence.
Clinical Trial Evidence
Currently no related clinical trials are registered for the top-ranked prediction (multiple endocrine neoplasia).
For reference, the only trial found across the predictions relates to HIV:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04385719 | Phase 2 | Completed | 24 | Pharmacokinetic study in healthy Ugandan volunteers of how tenofovir/lamivudine or atazanavir/ritonavir affect remdesivir blood levels. It is a drug-interaction study, not an HIV efficacy trial. |
Literature Evidence
Currently no related literature is available for the top-ranked prediction (multiple endocrine neoplasia).
For reference, selected publications retrieved for the HIV prediction (all concern COVID-19 rather than HIV treatment):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33264556 | 2021 | RCT | N Engl J Med | WHO Solidarity trial of repurposed antivirals, including remdesivir, in hospitalised COVID-19 patients |
| 38675889 | 2024 | RCT | Viruses | Resistance analysis of the Phase 3 SIMPLE trials. No remdesivir resistance was observed. |
| 35817072 | 2022 | RCT | Lancet Respir Med | Tixagevimab-cilgavimab versus placebo in hospitalised COVID-19 patients receiving remdesivir |
| 34696838 | 2021 | Review | The Enzymes | Mechanisms of nucleotide analogs inhibiting viral RNA replication, comparing SARS-CoV-2 RdRp with HIV reverse transcriptase |
| 34859557 | 2022 | Observational | HIV Med | High frequency of potential drug interactions between antiretrovirals and COVID-19 medications in HIV-positive patients |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02502143 | VEKLURY | Not stated | Not stated |
Safety Considerations
Drug Interactions: The interaction screen returned 100 interacting drugs. All of the first 20 listed are rated Moderate. Examples include:
- Antibiotics: doxycycline, minocycline, tetracycline, clarithromycin, vancomycin, levofloxacin, kanamycin, neomycin
- Antifungals: amphotericin B, amphotericin B (lipid complex)
- Antidiabetics: acarbose, pioglitazone
- Anabolic steroids: oxandrolone, oxymetholone
- Aminosalicylates: mesalazine, balsalazide, olsalazine
- Others: bupropion, naltrexone, chenodeoxycholic acid
Please refer to the package insert for warnings and contraindications. Its content was not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, multiple endocrine neoplasia, has no clinical trials, no literature and no plausible mechanism, so it is supported only by a TxGNN model (deep learning) score. The other predictions are either veterinary or non-viral diseases with no supporting evidence, or relate to remdesivir only in the context of COVID-19.
To proceed, the following is needed:
- The Health Canada package insert, to establish the approved indication, warnings and contraindications
- Mechanism of action data (for example from DrugBank)
- Preclinical or mechanistic evidence linking remdesivir to endocrine tumour biology, if this prediction is to be pursued
- Prioritisation of the CMV and HIV predictions for literature review. HIV evidence is currently limited to a pharmacokinetic interaction study, and CMV evidence to co-infection reports in COVID-19.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.